They were much higher previously yes, however if we could raise enough from Hervaxx/PD1-VAXX sales we may not see another dreaded CR again.
I would love to see an update on both of the B Cell trials that are ongoing.
Right now the aim is to be better than the previous best in market drug Herceptin (for Hervaxx).
7.5 months doesn't seem like a big target to reach. If there is a 25-40% increase in progression free survival to say 9.5 months/10.5 months, I feel with the patent expired for Herceptin and Hervaxx expiring in 2036 there may be some benefit for a Hervaxx sale to a potential buyer.
I think US $250-500million is reasonable with a potential for a small percentage in ongoing royalties.
Anything to avoid the share confetti cannon from coming out of storage is a bonus in my eyes.
IMU Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)